538 related articles for article (PubMed ID: 19967556)
1. Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer.
Botteri E; Sandri MT; Bagnardi V; Munzone E; Zorzino L; Rotmensz N; Casadio C; Cassatella MC; Esposito A; Curigliano G; Salvatici M; Verri E; Adamoli L; Goldhirsch A; Nolè F
Breast Cancer Res Treat; 2010 Jul; 122(1):211-7. PubMed ID: 19967556
[TBL] [Abstract][Full Text] [Related]
2. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.
Cohen SJ; Punt CJ; Iannotti N; Saidman BH; Sabbath KD; Gabrail NY; Picus J; Morse M; Mitchell E; Miller MC; Doyle GV; Tissing H; Terstappen LW; Meropol NJ
J Clin Oncol; 2008 Jul; 26(19):3213-21. PubMed ID: 18591556
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of circulating tumour cells enumerated after filtration enrichment in early and metastatic breast cancer patients.
Wong NS; Kahn HJ; Zhang L; Oldfield S; Yang LY; Marks A; Trudeau ME
Breast Cancer Res Treat; 2006 Sep; 99(1):63-9. PubMed ID: 16541316
[TBL] [Abstract][Full Text] [Related]
4. Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system?
Dawood S; Broglio K; Valero V; Reuben J; Handy B; Islam R; Jackson S; Hortobagyi GN; Fritsche H; Cristofanilli M
Cancer; 2008 Nov; 113(9):2422-30. PubMed ID: 18785255
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer.
Cristofanilli M; Hayes DF; Budd GT; Ellis MJ; Stopeck A; Reuben JM; Doyle GV; Matera J; Allard WJ; Miller MC; Fritsche HA; Hortobagyi GN; Terstappen LW
J Clin Oncol; 2005 Mar; 23(7):1420-30. PubMed ID: 15735118
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival.
Hayes DF; Cristofanilli M; Budd GT; Ellis MJ; Stopeck A; Miller MC; Matera J; Allard WJ; Doyle GV; Terstappen LW
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4218-24. PubMed ID: 16857794
[TBL] [Abstract][Full Text] [Related]
7. Multicentric and multifocal versus unifocal breast cancer: is the tumor-node-metastasis classification justified?
Weissenbacher TM; Zschage M; Janni W; Jeschke U; Dimpfl T; Mayr D; Rack B; Schindlbeck C; Friese K; Dian D
Breast Cancer Res Treat; 2010 Jul; 122(1):27-34. PubMed ID: 20454925
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.
De Giorgi U; Valero V; Rohren E; Dawood S; Ueno NT; Miller MC; Doyle GV; Jackson S; Andreopoulou E; Handy BC; Reuben JM; Fritsche HA; Macapinlac HA; Hortobagyi GN; Cristofanilli M
J Clin Oncol; 2009 Jul; 27(20):3303-11. PubMed ID: 19451443
[TBL] [Abstract][Full Text] [Related]
9. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
10. Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer.
Nakamura S; Yagata H; Ohno S; Yamaguchi H; Iwata H; Tsunoda N; Ito Y; Tokudome N; Toi M; Kuroi K; Suzuki E
Breast Cancer; 2010 Jul; 17(3):199-204. PubMed ID: 19649686
[TBL] [Abstract][Full Text] [Related]
11. Detection of circulating tumor cells in peripheral blood of heavily treated metastatic breast cancer patients.
Tokudome N; Ito Y; Takahashi S; Kobayashi K; Taira S; Tsutsumi C; Oto M; Oba M; Inoue K; Kuwayama A; Masumura K; Nakayama Y; Watanabe C; Hatake K
Breast Cancer; 2011 Jul; 18(3):195-202. PubMed ID: 21465230
[TBL] [Abstract][Full Text] [Related]
12. Circulating tumor cells in metastatic breast cancer: timing of blood extraction for analysis.
Martín M; García-Sáenz JA; Maestro De las Casas ML; Vidaurreta M; Puente J; Veganzones S; Rodríguez-Lajusticia L; De la Orden V; Oliva B; De la Torre JC; López-Tarruella S; Casado A; Sastre J; Díaz-Rubio E
Anticancer Res; 2009 Oct; 29(10):4185-7. PubMed ID: 19846970
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of residual breast disease and axillary node involvement for patients who had primary induction chemotherapy for advanced breast cancer.
Escobar PF; Patrick RJ; Rybicki LA; Hicks D; Weng DE; Crowe JP
Ann Surg Oncol; 2006 Jun; 13(6):783-7. PubMed ID: 16604475
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer.
Shiomi-Mouri Y; Kousaka J; Ando T; Tetsuka R; Nakano S; Yoshida M; Fujii K; Akizuki M; Imai T; Fukutomi T; Kobayashi K
Breast Cancer; 2016 Jan; 23(1):120-127. PubMed ID: 24906662
[TBL] [Abstract][Full Text] [Related]
15. Elevated preoperative serum ICTP is a prognostic factor for overall and disease-free survival in breast cancer.
Keskikuru R; Bloigu R; Risteli J; Kataja V; Jukkola A
Oncol Rep; 2002; 9(6):1323-7. PubMed ID: 12375042
[TBL] [Abstract][Full Text] [Related]
16. Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients.
Giordano A; Giuliano M; De Laurentiis M; Eleuteri A; Iorio F; Tagliaferri R; Hortobagyi GN; Pusztai L; De Placido S; Hess K; Cristofanilli M; Reuben JM
Breast Cancer Res Treat; 2011 Sep; 129(2):451-8. PubMed ID: 21710134
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
18. Survival analysis between patients with invasive ductal and invasive lobular breast cancer.
Dian D; Herold H; Mylonas I; Scholz C; Janni W; Sommer H; Friese K
Arch Gynecol Obstet; 2009 Jan; 279(1):23-8. PubMed ID: 18449551
[TBL] [Abstract][Full Text] [Related]
19. Circulating tumor cells, disease progression, and survival in metastatic breast cancer.
Cristofanilli M; Budd GT; Ellis MJ; Stopeck A; Matera J; Miller MC; Reuben JM; Doyle GV; Allard WJ; Terstappen LW; Hayes DF
N Engl J Med; 2004 Aug; 351(8):781-91. PubMed ID: 15317891
[TBL] [Abstract][Full Text] [Related]
20. Separating favorable from unfavorable prognostic markers in breast cancer: the role of E-cadherin.
Heimann R; Lan F; McBride R; Hellman S
Cancer Res; 2000 Jan; 60(2):298-304. PubMed ID: 10667580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
